These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3898491)

  • 1. Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients.
    Henny FC; Kleinbloesem CH; Moolenaar AJ; Paul LC; Breimer DD; van Es LA
    Transplantation; 1985 Sep; 40(3):261-5. PubMed ID: 3898491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cyclosporine kinetic profile. Failure to correlate with nephrotoxicity or rejection episodes following sequential immunotherapy for renal transplantation.
    Sommer BG; Sing DE; Henry ML; Ferguson RM; Orosz CG
    Transplantation; 1988 Jan; 45(1):86-90. PubMed ID: 3276069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism.
    Awni WM; Kasiske BL; Heim-Duthoy K; Rao KV
    Clin Pharmacol Ther; 1989 Jan; 45(1):41-8. PubMed ID: 2642778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients.
    Kasiske BL; Heim-Duthoy K; Rao KV; Awni WM
    Transplantation; 1988 Nov; 46(5):716-22. PubMed ID: 3057694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine.
    Kahan BD; Kramer WG; Wideman CA; Frazier OH; Lorber MI; Williams C; Flechner SM; Cooley DA; Van Buren CT
    Transplant Proc; 1986 Dec; 18(6 Suppl 5):115-9. PubMed ID: 3538563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomised comparative study on the influence of cyclosporin and azathioprine on renal allograft survival and function.
    Henny FC; Kootte AM; Van Bockel JH; Baldwin WM; Hermans J; Bos B; van Es LA; Paul LC
    Nephrol Dial Transplant; 1986; 1(1):44-9. PubMed ID: 3110662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective long-term immunosuppression maintained by low cyclosporine levels in primary cadaveric renal transplant recipients.
    Kupin WL; Venkat KK; Norris C; Florence-Green D; Dienst S; Oh HK; Feldkamp C; Levin NW
    Transplantation; 1987 Feb; 43(2):214-8. PubMed ID: 3544378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and tolerability of cyclosporine G in human kidney transplant recipients.
    Huser B; Thiel G; Oberholzer M; Beveridge T; Bianchi L; Mihatsch MJ; Landmann J
    Transplantation; 1992 Jul; 54(1):65-9. PubMed ID: 1631947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.
    Lindholm A; Dahlqvist R; Groth GG; Sjöqvist F
    Br J Clin Pharmacol; 1990 Sep; 30(3):443-52. PubMed ID: 2223423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal allograft dysfunction upon cyclosporine trough levels in host blood.
    Arnold AN; Waltzer WC; Anaise D; Weinstein SW; Rapaport FT
    Transplantation; 1985 Dec; 40(6):605-10. PubMed ID: 3907030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of nifedipine on renal function in normotensive cyclosporin-A-treated renal allograft recipients.
    McNally PG; Walls J; Feehally J
    Nephrol Dial Transplant; 1990; 5(11):962-8. PubMed ID: 2127834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of H2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients.
    Pachon J; Lorber MI; Bia MJ
    Transplantation; 1989 Feb; 47(2):254-9. PubMed ID: 2645708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients.
    Chan C; Maurer J; Cardella C; Cattran D; Pei Y
    Transplantation; 1997 May; 63(10):1435-40. PubMed ID: 9175807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients.
    Tortorice KL; Heim-Duthoy KL; Awni WM; Rao KV; Kasiske BL
    Ther Drug Monit; 1990 Jul; 12(4):321-8. PubMed ID: 2396304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose cyclosporine for cadaveric renal transplantation.
    Vanderwerf BA; Serota AI
    Transplantation; 1988 Feb; 45(2):320-3. PubMed ID: 3278422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection.
    Klintmalm G; Säwe J; Ringdén O; von Bahr C; Magnusson A
    Transplantation; 1985 Feb; 39(2):132-7. PubMed ID: 3881851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine-induced renal dysfunction in human renal allograft recipients.
    Kiberd BA
    Transplantation; 1989 Dec; 48(6):965-9. PubMed ID: 2688208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Oh HK; Dienst S
    Transplantation; 1988 Jan; 45(1):53-5. PubMed ID: 3276062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients.
    Ost L
    Transplantation; 1987 Oct; 44(4):533-5. PubMed ID: 3313841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.